Tratamiento con Amisulpride de pacientes adictos a sustancias psicoactivas y síntomas psicóticos

Sánchez Máñez, A; Palau Muñoz, C; Llorens Aleixandre, N; Dorado Garcia, M. L; Lizán Tudela, L; Romero Gómez, F. J.
Actas esp. psiquiatr ; 38(3): 138-146, mayo-jun. 2010. ilus, graf
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-83367

Documentos relacionados

  1. Validation of Population Pharmacokinetic Models for Clozapine Dosage Prediction.
  2. Relationship of Prolactin Concentrations to Steady-State Plasma Concentrations of Aripiprazole in Patients With Schizophrenia.
  3. Modeling Approach with Therapeutic Drug Monitoring Data to Describe Time Course of Clozapine Exposure and Positive and Negative Syndrome Scale Scores.
  4. Third Argentine Consensus statement on management Bipolar Disorders. Section 2 A: Comprehensive treatment of the bipolar disorders in adults
  5. How to classify antipsychotics: time to ditch dichotomies?
  6. Third Argentine Consensus statement on management Bipolar Disorders. Section1: introduction and general concepts
  7. A machine learning model for predicting blood concentration of quetiapine in patients with schizophrenia and depression based on real-world data.
  8. Effectiveness of Providing Information on Antipsychotic Medication to Patients with Psychotic Disorders: An Integrative Review.
  9. When to initiate antipsychotic treatment for psychotic symptoms: At the premorbid phase or first episode of psychosis?
  10. Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.